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procedural success was achieved in 98.3%. At twelve months, the rate
of cardiac death was 1.7% (1 patient), target vessel myocardial
infarction was 1.7% and TLR was also 1.7%, giving the TLF of (3.3%).
The cumulative incidence of deﬁnite/probable scaffold thrombosis
was 3.4% (2 patients). Both events happened within 10 days after
procedure.
CONCLUSIONS Stenting of coronary bifurcation lesions with bio-
resorbable everolimus-eluting scaffolds is feasible with excellent
acute performance and satisfactory early and long-term clinical out-
comes. The results of our study represent a major step forward to-
wards more complete implementation of BVS to coronary
interventions.
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BACKGROUND The illumination of the spontaneous vascular healing
pattern following implantation of an everolimus-eluting Absorb
bioresorbable vascular scaffold (BVS) remains sparse. Optical coher-
ence tomography (OCT) allows accurate and detailed in vivo assess-
ment of the arterial healing following BVS-implantation.
METHODS Serial OCT (after Absorb BVS implantation, 9- and 24-
month follow-up) was performed in 20 patients with stable angina
pectoris post implantation, at 9-month and after 24 months were
available in 18 patients. Dynamic changes in scaffold strut coverage
and major coronary evaginations were evaluated. Coronary evagina-
tions were deﬁned when the maximal depth of outward bulges of the
luminal contour between scaffold struts were >150 mm. Major evagi-
nations were deﬁned as presence of evaginations in 3 consecutive
analyzed frames, with a minimal evagination depth of 10% of the
nominal scaffold diameter.
RESULTS The lesion length was 14.4  3.4 mm and the scaffold length
was 19.7  4.2 mm. The scaffold size was 3.0  0.3 mm, maximum
balloon size was 3.3  0.3 mm and maximum balloon pressure was
14.5  2.6 atm. At baseline, 3,745 struts were analyzed. The median
percentage of uncovered struts was 5.1% [25th-75th percentiles: 0.5-
10.0%] after 9 months and 0.0% [0.0-0.0%] after 24 months.
Completely covered scaffolds were seen in 3 patients (16.7%) after 9
months and in 17 patients (94.4%) after 24 months (p¼0.001). The
median neointimal thickness increased from 9-month: 100 mm [70-120
mm] to 24-month: 115 mm [98-133 mm] (p¼0.013). The minimum lumen
area decreased signiﬁcantly from 5.2 mm2 [4.8-5.7 mm2] at post-im-
plantation to 4.4 mm2 [3.7-4.8 mm2] at 9-month (p¼0.003), while no
signiﬁcant change was observed from 9-month to 4.5 mm2 [3.6-
4.9 mm2] at 24 months, (p¼ns). Major coronary evaginations were
seen in 7 patients (38.9%) at 9-month follow-up and resolved in 6 out
of these 7 patients (85.7%) after 24 months.
CONCLUSIONS Almost complete scaffold strut coverage was present
at 24 months without causing long-term minimum lumen area
reduction. Major coronary evaginations were relatively frequent
morphological ﬁndings after 9 months and mainly resolved after 24
months.
CATEGORIES CORONARY: Bioresorbable Vascular Scaffolds
KEYWORDS OCT, Percutaneous coronary intervention, Vascular
healingTCT-544
Bioresorbable Coronary Devices in Clinical Practice: Immediate and 30-day
Results of the Prospective REPARA Registry
Felipe Hernandez,1 Armando Pérez de Prado,2 Pablo Salinas,3
Pablo Piñon,4 Joan Bassaganyas,5 Alfonso Torres Bosco,6
Pablo Avanzas,7 Juan Sanchis,8 Iñigo Lozano,9
Jose R. Lopez-Minguez,10 Koldo Gaviria,11 Monica Masotti,12
Leire Andraka,13 Juan H. Alonso Briales,14 Raul Moreno,15
Alberto Berenguer,16 Pedro Martinez Romero17
1Hospital 12 de Octubre, Madrid, Spain; 2HemoLeon, Fundación
Investigación Sanitaria en León, Leon, Leon; 3Hospital Clínico San
Carlos, Madrid, Spain; 4Complejo H de La Coruña, La Coruña, Spain;
5Hospital Josep Trueta, Gerona, AK; 6Hospital Txagorritxu, Vitoria, AK;
7Hospital Central de Asturias, Oviedo, Spain; 8Hospital Clinico de
Valencia, Valencia, Spain; 9Hospital de Cabueñes, Gijon, Gijon, AK;
10Infanta Cristina University Hospital, Badajoz, Spain; 11Policlinica
Guipuzcoa, San Sebastian, Spain; 12H Clinic Barcelona, Barcelona,
Spain; 13Hospital de Basurto, Bilbao, Spain; 14Hospital Virgen de la
Victoria, Malaga, Spain; 15University Hospital La Paz, Madrid, Madrid;
16University General Hospital of Valencia, Valencia, Spain; 17Puerta Del
Mar Hospital, Cadiz, Spain
BACKGROUND Bioresorbable coronary devices are currently being
used in selected lesions and patients. Routine use in daily clinical
practice has not yet been established and few data exist about speciﬁc
lesions and clinical scenarios.
METHODS REPARA is a multicenter, prospective registry, designed to
evaluate the efﬁcacy and safety of the bioresorbable coronary device
Absorb (Abbott Vascular, Santa Clara, California) in daily clinical
practice in more than 2400 patients undergoing elective coronary
intervention in native coronary arteries in Spain and Portugal. The
primary objective is a combined of MACE at 12 months, including
cardiac death, myocardial infarction, TLR and stent thrombosis.
RESULTS Complete data will be available at the time of the meeting.
By now, 1627 patients have been included (mean age 5711 years, 81%
male), 25% diabetics. Clinical indication was MI in 59% (STEMI in 32%,
non-STEMI in 27%), unstable angina in 18%, stable angina or silent
ischemia in 21% and others in 2%. Radial access was used in 83% of
patients. A total of 2159 lesions were treated (type A 22%, B1 38%, B2
26%, C 14%), mean 1.350.7 for patient, 51% in LAD, 21% in Cx and
28% in RCA. Mean lesion length was 18.19.1 mm, 13% were bi-
furcations, 10% complete occlusions and 3% ostial location. Lesion
predilatation was performed in 78% and 1.20.5 devices were
implanted in each lesion. Mean device length was 2313 mm and
mean device diameter 30.4 mm. Overlapping rate was 14% (67% for
total coverage of the lesion, 33% to treat proximal or distal dissection).
Balloon postdilatation rate was 40% (mean balloon diameter
3.30.4 mm, mean length 12.84 mm, mean pressure 17.65 atm).
Intracoronary imaging was performed in 12% of lesions (IVUS in 2.8%
and OCT in 9.1%), and malapposition was detected only in 0.3%.
Procedural success rate was 98.4%. In-hospital MACE were 1.6% (1.1%
periprocedural MI, 0.3% acute stent thrombosis, 0.2% TLR and 0.2%
cardiac deaths). At 30 days (1479 patients) total adverse events were
2.4% (1.6% MI, 0.9% stent thrombosis, 0.8% TLR and 0.3% cardiac
deaths). At discharge, all patients were receiving double antiplatelet
therapy (ASA 100%, clopidogrel 57%, ticagrelor 27%, prasugrel 16%).
Subgroup analyses by patient and lesion complexities will be
provided.
CONCLUSIONS Results from this large real-world registry with bio-
resorbable coronary devices show good immediate and 30-day out-
comes in unselected lesions and with a high rate of ACS patients. Early
stent thrombosis rates are comparable to those reported with drug-
eluting stents.
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